Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGRX NASDAQ:HYPD NASDAQ:MIRA NASDAQ:SCYX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGRXAgile Therapeutics$1.51$1.49$0.20▼$2.63$10.35M1.58352,864 shsN/AHYPDHyperion DeFi$2.34-3.3%$3.15$2.34▼$15.00$35.47M2.49453,797 shs361,638 shsMIRAMIRA Pharmaceuticals$0.84+0.2%$0.96$0.83▼$2.45$35.36M1.48131,499 shs49,474 shsSCYXSCYNEXIS$3.77+3.9%$4.49$3.53▼$10.48$37.44M1.1169,019 shs46,972 shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGRXAgile Therapeutics0.00%0.00%0.00%0.00%0.00%HYPDHyperion DeFi-5.47%-12.32%-20.00%-38.89%-74.53%MIRAMIRA Pharmaceuticals-4.78%-8.39%-16.85%-17.67%-51.17%SCYXSCYNEXIS+1.68%-10.37%-5.71%-51.43%-38.06%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGRXAgile Therapeutics$1.51$1.49$0.20▼$2.63$10.35M1.58352,864 shsN/AHYPDHyperion DeFi$2.34-3.3%$3.15$2.34▼$15.00$35.47M2.49453,797 shs361,638 shsMIRAMIRA Pharmaceuticals$0.84+0.2%$0.96$0.83▼$2.45$35.36M1.48131,499 shs49,474 shsSCYXSCYNEXIS$3.77+3.9%$4.49$3.53▼$10.48$37.44M1.1169,019 shs46,972 shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGRXAgile Therapeutics0.00%0.00%0.00%0.00%0.00%HYPDHyperion DeFi-5.47%-12.32%-20.00%-38.89%-74.53%MIRAMIRA Pharmaceuticals-4.78%-8.39%-16.85%-17.67%-51.17%SCYXSCYNEXIS+1.68%-10.37%-5.71%-51.43%-38.06%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGRXAgile Therapeutics 0.00N/AN/AN/AHYPDHyperion DeFi 2.25Hold$6.95197.01% UpsideMIRAMIRA Pharmaceuticals 2.00HoldN/AN/ASCYXSCYNEXIS 2.00Hold$24.00536.60% UpsideCurrent Analyst Ratings BreakdownLatest AGRX, SCYX, MIRA, and HYPD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/24/2026SCYXSCYNEXIS Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)7/14/2026HYPDHyperion DeFi Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold7/10/2026SCYXSCYNEXIS Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)7/1/2026HYPDHyperion DeFi Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$4.00 ➝ $6.606/26/2026SCYXSCYNEXIS Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/24/2026HYPDHyperion DeFi Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/24/2026MIRAMIRA Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/12/2026SCYXSCYNEXIS Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/8/2026HYPDHyperion DeFi Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$8.25 ➝ $7.305/20/2026HYPDHyperion DeFi Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 7/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGRXAgile Therapeutics$19.98M0.52N/AN/A($5.51) per share-0.27HYPDHyperion DeFi$810K43.80N/AN/A$4.73 per share0.49MIRAMIRA PharmaceuticalsN/AN/AN/AN/A$0.25 per shareN/ASCYXSCYNEXIS$20.34M1.84N/AN/A$9.07 per share0.42Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGRXAgile Therapeutics-$14.47M-$3.65N/AN/AN/A-36.24%N/A-147.37%N/AHYPDHyperion DeFi-$45.31M-$9.95N/A2.03N/AN/A-91.59%-73.08%N/AMIRAMIRA Pharmaceuticals-$10.44M-$1.30N/AN/AN/AN/A-140.82%-135.01%9/2/2026 (Estimated)SCYXSCYNEXIS-$8.61M-$3.84N/AN/AN/A-41.79%-57.16%-39.48%8/12/2026 (Estimated)Latest AGRX, SCYX, MIRA, and HYPD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2026Q2 2026SCYXSCYNEXIS-$0.5067N/AN/AN/A$0.08 millionN/A5/14/2026Q1 2026MIRAMIRA PharmaceuticalsN/A-$0.03N/A-$0.03N/AN/A5/11/2026Q1 2026SCYXSCYNEXIS-$0.10-$0.42-$0.32-$3.36$0.08 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAGRXAgile TherapeuticsN/AN/AN/AN/AN/AHYPDHyperion DeFiN/AN/AN/AN/AN/AMIRAMIRA PharmaceuticalsN/AN/AN/AN/AN/ASCYXSCYNEXISN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGRXAgile TherapeuticsN/A0.560.38HYPDHyperion DeFi0.121.971.97MIRAMIRA PharmaceuticalsN/A82.1582.15SCYXSCYNEXISN/A3.943.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGRXAgile Therapeutics10.92%HYPDHyperion DeFi25.84%MIRAMIRA Pharmaceuticals35.16%SCYXSCYNEXIS54.37%Insider OwnershipCompanyInsider OwnershipAGRXAgile Therapeutics0.50%HYPDHyperion DeFi7.50%MIRAMIRA Pharmaceuticals6.65%SCYXSCYNEXIS4.09%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGRXAgile Therapeutics306.86 million6.82 millionNot OptionableHYPDHyperion DeFi4015.16 million14.02 millionNo DataMIRAMIRA Pharmaceuticals242.02 million39.23 millionNot OptionableSCYXSCYNEXIS609.93 million9.52 millionOptionableAGRX, SCYX, MIRA, and HYPD HeadlinesRecent News About These CompaniesSCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)June 30, 2026 | globenewswire.comSCYNEXIS Shareholders Approve Governance and Equity Plan ChangesJune 26, 2026 | tipranks.comSCYNEXIS Inc.June 24, 2026 | marketwatch.comSCYNEXIS Announces One-for-Eight Reverse Stock SplitMay 22, 2026 | globenewswire.comSCYNEXIS (SCYX) price target increased by 20.73% to 4.28May 14, 2026 | msn.comSCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 11, 2026 | globenewswire.comSCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)May 6, 2026 | globenewswire.comSCYNEXIS Raises $40 Million in Strategic Private PlacementApril 19, 2026 | theglobeandmail.comSCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics TranscriptMarch 31, 2026 | seekingalpha.comSCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney ...March 31, 2026 | markets.businessinsider.comWhy did SCYX stock jump 10% in pre-market today?March 31, 2026 | msn.comPoxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 MillionMarch 31, 2026 | businesswire.comSCYNEXIS Announces $40.0 Million Private PlacementMarch 31, 2026 | globenewswire.comSCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)March 31, 2026 | globenewswire.comSCYNEXIS, Inc. (SCYX) Announces First Participants Dosed in Phase 1 Trial of SCY-247 Antifungal TherapyMarch 12, 2026 | insidermonkey.comScynexis: Q4 Earnings SnapshotMarch 4, 2026 | wiltonbulletin.comWSCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate UpdateMarch 4, 2026 | globenewswire.comSCYNEXIS, Inc. Initiates Phase 1 Trial for Intravenous Antifungal SCY-247 Following FDA DesignationsFebruary 26, 2026 | quiverquant.comQSCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247February 26, 2026 | globenewswire.comCERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of DirectorsFebruary 17, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAGRX, SCYX, MIRA, and HYPD Company DescriptionsAgile Therapeutics NASDAQ:AGRXAgile Therapeutics, Inc., a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.Hyperion DeFi NASDAQ:HYPD$2.34 -0.08 (-3.31%) Closing price 04:00 PM EasternExtended Trading$2.35 +0.01 (+0.21%) As of 04:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.MIRA Pharmaceuticals NASDAQ:MIRA$0.84 +0.00 (+0.21%) Closing price 04:00 PM EasternExtended Trading$0.85 +0.01 (+1.00%) As of 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.SCYNEXIS NASDAQ:SCYX$3.77 +0.14 (+3.86%) Closing price 04:00 PM EasternExtended Trading$3.78 +0.00 (+0.13%) As of 04:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why SK hynix Could Be the Best AI Chip Stock to Buy Now Why Bloom Energy May Be the Most Important AI Infrastructure Stock Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead? Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters Broadcom’s $200 Billion Samsung Deal Shows How Costly the AI Memory Race Has Become Meta’s AI Spending Problem Just Found a BlackRock Solution Carrier Earnings Could Send the Stock to a New All-Time High Amazon’s Satellite Push Raises the Stakes for SpaceX and AST SpaceMobile Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
